Medicare does not cover GLP-1 medications for weight loss under Part D, although the Medicare Bridge Program launched July 1, 2026 provides $50 per month for Wegovy pen, Wegovy pill, Zepbound KwikPen, and Foundayo for eligible Medicare beneficiaries with BMI 27 and above and an obesity-related comorbidity, running through December 31, 2027 (PeptideDeck)
But "works" depends entirely on using it correctly
This legal action is under the oversight of the United States Judicial Panel on Multidistrict Litigation, which determined that centralizing the cases would promote the just and efficient conduct of the litigation
For references and more information , see the section on Chromium in the Pregnancy and Lactation article
Rosenberg says
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults